구제역 백신 시장 : 백신 유형, 대상 동물, 투여 경로, 용도, 유통 채널, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Foot & Mouth Disease Vaccines Market is projected to grow by USD 6.01 billion at a CAGR of 9.38% by 2032.

Foot and mouth disease vaccines remain central to livestock biosecurity because FMD is a highly contagious transboundary animal disease affecting cattle, pigs, sheep, goats, buffalo, and susceptible wildlife. According to WOAH and FAO guidance, vaccination is most effective when paired with surveillance, movement control, rapid diagnostics, and strong veterinary governance.

The market is shaped by seven immunologically distinct FMD virus serotypes, regional strain diversity, and the need for antigenically matched vaccines. Demand is strongest where endemic risk, cattle density, export protection, and government-led immunization programs converge, particularly in regions where livestock production is closely linked to food security, rural livelihoods, and access to international trade.

Transformative Shifts in the FMD Vaccine Landscape

The FMD vaccines landscape is shifting from reactive outbreak response toward prevention-led disease control. Governments are expanding vaccine banks, strengthening cold-chain readiness, and aligning national programs with WOAH-recognized FMD control pathways to protect meat, dairy, and live-animal trade.

Manufacturers are competing on high-potency formulations, purified inactivated vaccines, multivalent coverage, and validated quality systems. At the same time, DIVA-compatible strategies, improved diagnostics, and molecular epidemiology are making vaccine selection more evidence-driven and region-specific, helping veterinary authorities connect field surveillance with targeted vaccination policies.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is improving how FMD vaccine decisions are made by connecting genomic surveillance, outbreak reports, animal movement data, climate-linked risk indicators, and vaccine inventory signals. AI-supported analytics can help identify circulating lineages, prioritize antigen matching, and model where emergency vaccination would reduce spread most efficiently.

In manufacturing and distribution, AI can support batch consistency monitoring, demand planning, cold-chain risk detection, and procurement coordination. Its value depends on validated datasets, veterinary oversight, and responsible integration with laboratory-confirmed epidemiology rather than replacing expert judgment.

Key Regional Insights

Asia-Pacific represents a major demand center because China, India, and parts of Southeast Asia combine large livestock populations with persistent FMD risk, while Australia and Japan maintain strict freedom programs through border biosecurity, surveillance, and emergency preparedness. North America is largely FMD-free and focuses on preparedness, vaccine banks, diagnostic readiness, surveillance, and rapid response capacity to protect livestock production and trade continuity.

Latin America continues to advance FMD-free recognition and export protection, with Brazil playing a pivotal role in cattle-sector disease policy and progressive vaccination-to-surveillance transitions in recognized zones. Europe emphasizes non-routine vaccination, rapid detection, movement controls, and contingency planning under harmonized animal-health frameworks. The Middle East faces import-related and transboundary risk due to livestock movement and regional trade flows, while Africa remains strategically important because multiple FMD serotypes circulate across pastoral, smallholder, and cross-border livestock systems, making antigen matching and coordinated vaccination essential.

Key Group Insights

ASEAN markets are shaped by cross-border animal movement, smallholder livestock systems, and coordinated disease-control needs, especially where cattle, buffalo, and pig production intersect with informal trade routes. The GCC emphasizes import security, veterinary surveillance, quarantine capacity, and contingency access to vaccines to reduce exposure from animal and animal-product movements. The European Union sets a high regulatory benchmark through harmonized animal-health law, laboratory networks, diagnostic capacity, traceability, and emergency preparedness.

BRICS countries are influential because they include major livestock producers, large vaccination programs, expanding animal-health manufacturing capabilities, and significant exposure to food security and trade-protection priorities. G7 countries drive innovation, funding, reference-laboratory collaboration, and biosecurity standards, while NATO members increasingly treat animal disease preparedness as part of broader resilience for food supply chains, civil protection, and critical infrastructure continuity.

Key Country Insights

The United States and Canada remain focused on FMD freedom, vaccine-bank access, diagnostic readiness, simulation exercises, and emergency response planning, while Mexico maintains FMD-free status through border controls, surveillance, and coordinated animal-health safeguards. Brazil is central to Latin American progress, supported by decades of coordinated vaccination, surveillance policy, zoning, and export-oriented disease-control governance.

In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on EU-aligned or comparable controls, rapid diagnostics, traceability, movement restrictions, and contingency vaccination rather than routine use. Russia manages risk across diverse livestock zones and long land borders. China and India sustain large-scale immunization needs due to livestock density and endemic exposure, Japan and Australia prioritize exclusion through strict biosecurity and emergency preparedness, and South Korea combines surveillance with vaccination informed by prior outbreak experience and intensive livestock production systems.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize antigen matching, regional strain intelligence, and partnerships with national veterinary authorities. Investment in validated multivalent vaccines, high-potency emergency products, secure antigen reserves, and reliable cold-chain systems will be critical for both endemic control and outbreak preparedness.

Organizations should also strengthen pharmacovigilance, DIVA-aligned testing support, field effectiveness monitoring, and transparent quality documentation. Commercial strategies should reflect public procurement cycles, export-market disease requirements, regulatory expectations, and the practical realities of vaccine delivery across smallholder, intensive, and transboundary livestock systems.

Research Methodology

Research methodology is built from verified secondary research, including WOAH and FAO disease-control guidance, national veterinary authority publications, peer-reviewed scientific literature, reference-laboratory updates, and publicly available policy documents on FMD surveillance, vaccination, diagnostics, and emergency preparedness.

The analysis emphasizes triangulation across epidemiology, regulatory frameworks, procurement behavior, livestock demographics, serotype and lineage circulation, vaccine technology trends, and trade-related animal-health requirements. Market interpretation excludes unsupported revenue claims and focuses on evidence-backed drivers such as disease status, vaccination policy, biosecurity readiness, antigenic matching, and trade-protection incentives.

Conclusion

Foot and mouth disease vaccines are essential tools for protecting livestock health, food security, rural economies, and international animal-product trade. Their effectiveness depends on matching vaccines to circulating strains, maintaining quality-assured supply, and embedding immunization within broader surveillance, diagnostics, movement control, and biosecurity systems.

The strongest opportunities will emerge for manufacturers and public-sector partners that combine scientific credibility, regional preparedness, digital intelligence, regulatory alignment, and dependable field execution. As FMD risk remains uneven across regions, the market will continue to reward evidence-based, adaptable, and policy-aligned vaccine strategies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Foot & Mouth Disease Vaccines Market, by Vaccine Type

• 7.1. Conventional Vaccines
  • 7.1.1. Inactivated (Killed) Vaccines
  • 7.1.2. Oil-Based Vaccines
  • 7.1.3. Aluminum Hydroxide/Saponin-Based Vaccines
• 7.2. Modified / Attenuated Live Vaccines
• 7.3. Recombinant Vaccines
• 7.4. Emergency Vaccines

8. Foot & Mouth Disease Vaccines Market, by Animal Type

• 8.1. Cattle
• 8.2. Swine
• 8.3. Sheep & goats

9. Foot & Mouth Disease Vaccines Market, by Route Of Administration

• 9.1. Injection
• 9.2. Oral

10. Foot & Mouth Disease Vaccines Market, by Application

• 10.1. Preventive
• 10.2. Therapeutic

11. Foot & Mouth Disease Vaccines Market, by Distribution Channel

• 11.1. Offline
  • 11.1.1. Department Stores
  • 11.1.2. Direct Sales
  • 11.1.3. Specialty Stores
• 11.2. Online
  • 11.2.1. Company Websites
  • 11.2.2. E-commerce Platforms

12. Foot & Mouth Disease Vaccines Market, by End User

• 12.1. Clinics
• 12.2. Hospitals
• 12.3. Research Institutes

13. Foot & Mouth Disease Vaccines Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Foot & Mouth Disease Vaccines Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Foot & Mouth Disease Vaccines Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Agrovet Market Animal Health S.A.
• 17.2. Bayer AG
• 17.3. BIGVET Biotech Co., Ltd.
• 17.4. Biogenesis Bago S.A.
• 17.5. Biovet Private Limited
• 17.6. Boehringer Ingelheim International GmbH
• 17.7. Botswana Vaccine Institute
• 17.8. Brilliant Bio Pharma Limited
• 17.9. Cavet Bio Co., Ltd.
• 17.10. Ceva Sante Animale S.A.
• 17.11. China Animal Husbandry Industry Co., Ltd.
• 17.12. Godrej Agrovet Limited
• 17.13. Hester Biosciences Limited
• 17.14. Indian Immunologicals Limited
• 17.15. Inner Mongolia Biwei Antai Biotechnology Co., Ltd.
• 17.16. Inovet BV
• 17.17. Intervac Pvt. Ltd.
• 17.18. Jinyu Bio-Technology Co., Ltd.
• 17.19. Limor de Colombia S.A.
• 17.20. Merck & Co., Inc.
• 17.21. Middle East Vaccines Company
• 17.22. Phibro Animal Health Corporation
• 17.23. Selevac Pty Ltd
• 17.24. Shen Lian Biotechnology Co., Ltd.
• 17.25. Tecon Biology Co., Ltd.
• 17.26. VECOL S.A.
• 17.27. VETAL Animal Health Products Inc.
• 17.28. Zoetis Inc.